Supplemental material
Acta Oncologica
Volume 62, 2023 - Issue 9
Original Articles: Clinical Oncology
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
Louise Raunkildea Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark;b Danish Colorectal Cancer Center South, Vejle Hospital, Denmark;c Department of Regional Health Research, University of Southern Denmark, Odense, DenmarkCorrespondence[email protected]
https://orcid.org/0000-0001-9927-0673View further author information
https://orcid.org/0000-0001-9927-0673View further author information, Torben Frøstrup Hansena Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark;b Danish Colorectal Cancer Center South, Vejle Hospital, Denmark;c Department of Regional Health Research, University of Southern Denmark, Odense, Denmarkhttps://orcid.org/0000-0001-7476-671XView further author information
https://orcid.org/0000-0001-7476-671XView further author information, Birgitte Mayland Havelunda Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark;b Danish Colorectal Cancer Center South, Vejle Hospital, Denmarkhttps://orcid.org/0000-0002-6566-5367View further author information
https://orcid.org/0000-0002-6566-5367View further author information, Caroline Brenner Thomsena Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark;b Danish Colorectal Cancer Center South, Vejle Hospital, Denmarkhttps://orcid.org/0000-0003-4481-6274View further author information
https://orcid.org/0000-0003-4481-6274View further author information, Søren Rafael Rafaelsenb Danish Colorectal Cancer Center South, Vejle Hospital, Denmark;c Department of Regional Health Research, University of Southern Denmark, Odense, Denmark;d Department of Radiology, Vejle Hospital, University Hospital of Southern Denmark, Denmarkhttps://orcid.org/0000-0001-5182-5545View further author information
https://orcid.org/0000-0001-5182-5545View further author information, Jan Lindebjergb Danish Colorectal Cancer Center South, Vejle Hospital, Denmark;c Department of Regional Health Research, University of Southern Denmark, Odense, Denmark;e Department of Pathology, Vejle Hospital, University Hospital of Southern Denmark, Denmarkhttps://orcid.org/0000-0002-2055-4241View further author information
https://orcid.org/0000-0002-2055-4241View further author information & Lars Henrik Jensena Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark;b Danish Colorectal Cancer Center South, Vejle Hospital, Denmark;c Department of Regional Health Research, University of Southern Denmark, Odense, Denmarkhttps://orcid.org/0000-0002-0020-1537View further author information
https://orcid.org/0000-0002-0020-1537View further author information show all